Welcome to our dedicated page for Centessa Pharmaceuticals news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals stock.
Centessa Pharmaceuticals plc reports developments as a clinical-stage pharmaceutical company focused on orexin receptor 2 (OX2R) agonists for neuroscience indications. Company news centers on its OX2R pipeline, including preclinical data and therapeutic areas tied to excessive daytime sleepiness, impaired attention, cognitive deficits, fatigue, mood symptoms, and related neurological, neurodegenerative, and neuropsychiatric disorders.
Recurring updates also include investor conference participation, leadership and board governance changes, American Depositary Share offerings, capital-structure activity, material agreements, shareholder voting matters, and operating and financial results for its Nasdaq-listed ADSs.
Actinium (NYSE American: ATNM) appointed Steffen Heeger MD, MSc as Chief Medical Officer to guide its targeted radiotherapy pipeline. Heeger has led oncology programs from IND to global approvals, including work on Erbitux®, PSMA radiotherapies, and multiple hematologic and solid tumor assets.
According to Actinium, his experience aligns with advancing Actimab-A, ATNM-400, and Iomab-ACT toward key data readouts and expanded clinical trials in 2H 2026.
Eli Lilly (NYSE: LLY) agreed to acquire Centessa Pharmaceuticals for $38.00 cash per share plus one CVR, yielding up to $47.00 per share if regulatory milestones are met. The upfront consideration implies an aggregate equity value of ~$6.3 billion and the CVR adds potential ~$1.5 billion.
The deal expands Lilly's neuroscience footprint into sleep medicine by adding Centessa's OX2R agonist portfolio, including lead candidate cleminorexton (Phase 2a) targeting narcolepsy and idiopathic hypersomnia. Closing is expected in Q3 2026, subject to shareholder, High Court and regulatory approvals.
Centessa Pharmaceuticals (Nasdaq: CNTA) said members of management will participate in multiple investor conferences in Feb–Mar 2026, including Guggenheim Emerging Outlook: Biotech Summit (Feb 12), TD Cowen Health Care (Mar 3), Leerink Global Healthcare (Mar 10) and Jefferies Biotech on the Beach (Mar 11).
According to Centessa, live webcasts and archived recordings will be posted under the Events and Publications tab on the company investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced new preclinical data presented at the 64th ACNP Annual Meeting on Jan 14, 2026 showing that a highly potent, selective OX2R agonist reduced behavioral despair and enhanced wakefulness in established animal models of major depressive disorder. The results support OX2R activation as a potential rapid‑onset mechanism to improve mood symptoms and alleviate hypersomnolence and related deficits across neuropsychiatric indications. The poster "CNT-9982, an orexin receptor 2 agonist..." was presented by Sarah Wurts Black, PhD, and will be posted on the company's investor site after the presentation.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced a CEO transition effective January 1, 2026, appointing Mario Alberto Accardi PhD, president and founder of Centessa’s Orexin Program, as CEO and board member; outgoing CEO Saurabh Saha MD PhD will step down and serve as advisor.
The company is refocusing from a diversified early-stage pipeline to a pure-play orexin portfolio. Key program milestones: a registrational program for ORX750 is expected to start in Q1 2026, and clinical progress on ORX142 and ORX489 targets neurodegenerative and neuropsychiatric indications with milestones planned in 2026. Dr. Accardi previously led Orexia Therapeutics, raising €40M Series A and leading its acquisition by Centessa in 2021.
Centessa Pharmaceuticals (Nasdaq: CNTA) priced an underwritten public offering of 11,627,907 ADSs at $21.50 per ADS, generating approximately $250 million in gross proceeds before underwriting discounts, commissions and offering expenses. The company granted underwriters a 30-day option for up to 1,744,186 additional ADSs. The offering is expected to close on or about November 14, 2025, subject to customary closing conditions. The ADSs are being offered under a Form S-3 registration statement filed on September 11, 2024. Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint book-running managers.
Centessa Pharmaceuticals (Nasdaq: CNTA) on Nov 11, 2025 commenced an underwritten public offering of American Depositary Shares (each ADS representing one ordinary share). All ADSs are being offered by Centessa and the company intends to grant underwriters a 30-day option to purchase up to an additional 15% overallotment. The offering is subject to market and other conditions and there is no assurance it will be completed or as to final size or terms.
Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint book-running managers; Oppenheimer, Truist Securities and LifeSci Capital are co-leads. The ADSs are offered under a Form S-3 registration statement filed Sep 11, 2024 that became automatically effective.
Centessa Pharmaceuticals (Nasdaq: CNTA) said members of management will participate in multiple investor conferences in November–December 2025, giving live fireside chats and webcasts. Key events and times:
- Guggenheim Healthcare Innovation — Nov 12, 2025, 10:30 AM ET
- Jefferies Global Healthcare (London) — Nov 18, 2025, 2:00 PM GMT / 9:00 AM ET
- Piper Sandler Healthcare — Dec 2, 2025, 3:00 PM ET
- Evercore Healthcare — Dec 3, 2025, 9:35 AM ET
- Oppenheimer Movers in Rare Disease Summit — Dec 11, 2025
Centessa Pharmaceuticals (Nasdaq: CNTA) reported Q3 2025 results and clinical updates on its orexin receptor 2 (OX2R) agonist program on November 5, 2025. The company reported $349.0M in cash, cash equivalents and investments as of September 30, 2025, expected to fund operations into mid-2027. Centessa disclosed Phase 2a interim data for ORX750 (55 participants across NT1, NT2, IH) showing statistically significant, dose-dependent improvements on the MWT, ESS and weekly cataplexy rate (example: NT1 1.5 mg cohort, >20 minute MWT change, p=0.0026; 87% WCR reduction, p=0.0025). ORX142 Phase 1 (89 volunteers) showed significant MWT improvements. Company expects to initiate ORX750 registrational program and ORX142/ORX489 patient studies in Q1 2026. Q3 R&D was $41.6M; net loss was $54.9M.
Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management team will engage in a fireside chat on Tuesday, September 9th at 4:50 PM ET.
Investors and interested parties can access the live audio webcast and archived recording through the "Events & Presentations" section on Centessa's investor relations website.